The stable and quick delivery of high-quality products is a necessity for the development of self-care society.
Sato’s two major production bases in Japan, the Hachioji and Kazusa factories, along with its international production facility in Taiwan, have been linked to establish a global production network that can operate securely.
Hachioji factory: expansion of facilities and globalization at Sato’s main factory
To keep up with new products launches and changes in the marketplace, Sato has expanded its facilities in the Hachioji factory, including the plant’s production lines. The factory includes facilities such as a drink production line, ointment wing, formulation wing and the production line for Acess and other products. Sato’s production facilities have been strengthened by Japan’s fastest production lines, guaranteeing effective production and stable supply.
To increase production volumes, we will acquire land for a new factory and start construction in 2020. This new manufacturing facility is planned to be equipped with automated production lines for Acess and external pharmaceutical products complying with global GMP.
Sato installed an empty-bottle inspection system for drink products to ensure high quality. A system to constantly monitor the production environment for filling sterile eye drop containers has been introduced.
The factory’s production systems are compliant with global standards such as the Good Manufacturing Practices (GMP) widely adapted by countries and regions including the USA (FDA), Australia, the EU, and Canada. This enables Sato to further drive the supply of its products globally.
Kazusa factory: a high-tech next-generation production center using state-of-the-art equipment
Located in the rolling green setting of the Kazusa Akademia Park in Chiba Prefecture, across the bay from Tokyo, the Kazusa Factory is a next-generation facility featuring the latest technologies.
The production facilities in its drink production wing and external-use wing use IT technologies that make the entire process almost completely automated. Thus, the factory functions somewhat like an enormous robot.
To expand the sale of LUCONAC Solution 5%, we established a new line of ethical pharmaceutical products for external use. Production began in October 2017.
Taiwan factory: compliant with global PIC/S-GMP standards
Sato’s Taiwan factory, which operates as the production base for Asian markets, uses the same equipment and management system as the Hachioji factory, helping to ensure reliable, high-quality products.
Using the Pharmaceutical Inspection Co-operation Scheme (PIC/S) international instruments, the factory achieved conformity with global Good Manufacturing Practices (GMP) in 2014. In 2016, it was qualified once again with a renewed certificate.